Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Multimodal Treatment of Upper Gastrointestinal Signet Ring Cell Containing Cancer—Better Together

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  CAS  PubMed  Google Scholar 

  2. Schmidt T, Sisic L, Blank S, et al. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer. 2014;110:1712–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Messager M, Lefevre JH, Pichot-Delahaye V, et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg. 2011;254:684–93.

    Article  PubMed  Google Scholar 

  4. Heger U, Blank S, Wiecha C, et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol. 2014;21:1739–48.

    Article  PubMed  Google Scholar 

  5. Heger U, Sisic L, Nienhüser H, et al. Neoadjuvant therapy improves outcomes in locally advanced signet ring cell containing esophagogastric adenocarcinomas. Ann Surg Oncol. 2018;25:2418–27.

    Article  PubMed  Google Scholar 

  6. Piessen G, Messager M, Le Malicot K, et al. Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus perioperative chemotherapy for resectable gastric signet ring cell adenocarcinomas: PRODIGE 19–FFCD1103–ADCI002. BMC Cancer. 2013;13:281.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Al-Batran SE, Pauligk C, Homann N, et al. LBA27_PRDocetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). Ann Oncol. 2017;28:mdx440.019.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General, Visceral and Transplantation Surgery, University Hospital, Heidelberg, Germany

    Ulrike Heger MD & Thomas Schmidt MD, PhD

Authors
  1. Ulrike Heger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Schmidt MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Schmidt MD, PhD.

Ethics declarations

Disclosure

The authors declare that they have no conflict of interest.

Additional information

ASO Author Reflections offer a brief invited commentary on the article, “Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet Ring Cell Containing Esophagogastric Adenocarcinomas”. Ann Surg Oncol. 2018;25:2418–27.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heger, U., Schmidt, T. ASO Author Reflections: Multimodal Treatment of Upper Gastrointestinal Signet Ring Cell Containing Cancer—Better Together. Ann Surg Oncol 25 (Suppl 3), 761–762 (2018). https://doi.org/10.1245/s10434-018-6990-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6990-8

Keywords

Search

Navigation